Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Essential Thrombocythemia: The Dermatologic Point of View.

Cozzani E, Iurlo A, Merlo G, Cattaneo D, Burlando M, Pierri I, Gugliotta L, Parodi A.

Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):739-47. doi: 10.1016/j.clml.2015.08.086. Epub 2015 Sep 3. Review.

PMID:
26432058
2.

Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.

Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E, Elena C, Pierri I, Assouline S, D'Emilio A, Gozzini A, Giraldo P, Stagno F, Iurlo A, Luciani M, De Riso G, Redaelli S, Kim DW, Pirola A, Mezzatesta C, Petroccione A, Lodolo D'Oria A, Crivori P, Piazza R, Gambacorti-Passerini C.

Am J Hematol. 2015 Oct;90(10):910-4. doi: 10.1002/ajh.24120. Epub 2015 Sep 10.

3.

APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells.

Cagnetta A, Caffa I, Acharya C, Soncini D, Acharya P, Adamia S, Pierri I, Bergamaschi M, Garuti A, Fraternali G, Mastracci L, Provenzani A, Zucal C, Damonte G, Salis A, Montecucco F, Patrone F, Ballestrero A, Bruzzone S, Gobbi M, Nencioni A, Cea M.

Clin Cancer Res. 2015 Sep 1;21(17):3934-45. doi: 10.1158/1078-0432.CCR-14-3023. Epub 2015 May 11.

4.

Pyoderma gangrenosum-like CD30+  cutaneous T-cell lymphoma in a patient with mycosis fungoides.

Cozzani E, Scaparro M, Rongioletti F, Pierri I, Pimpinelli N, Parodi A.

J Eur Acad Dermatol Venereol. 2015 Apr;29(4):819-21. doi: 10.1111/jdv.12418. Epub 2014 Feb 27. No abstract available.

PMID:
24576263
5.

Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages.

Giannoni P, Pietra G, Travaini G, Quarto R, Shyti G, Benelli R, Ottaggio L, Mingari MC, Zupo S, Cutrona G, Pierri I, Balleari E, Pattarozzi A, Calvaruso M, Tripodo C, Ferrarini M, de Totero D.

Haematologica. 2014 Jun;99(6):1078-87. doi: 10.3324/haematol.2013.091405. Epub 2014 Feb 21.

6.

Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas.

Musso A, Catellani S, Canevali P, Tavella S, Venè R, Boero S, Pierri I, Gobbi M, Kunkl A, Ravetti JL, Zocchi MR, Poggi A.

Haematologica. 2014 Jan;99(1):131-9. doi: 10.3324/haematol.2013.097311. Epub 2013 Oct 25.

7.

Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.

Malagola M, Breccia M, Skert C, Cancelli V, Soverini S, Iacobucci I, Cattina F, Liberati AM, Tiribelli M, Annunziata M, Trabacchi E, De Vivo A, Castagnetti F, Martinelli G, Fogli M, Stagno F, Pica G, Iurlo A, Pregno P, Abruzzese E, Pardini S, Bocchia M, Russo S, Pierri I, Lunghi M, Barulli S, Merante S, Mandelli F, Alimena G, Rosti G, Baccarani M, Russo D.

Am J Hematol. 2014 Feb;89(2):119-24. doi: 10.1002/ajh.23593.

8.

Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status.

Cea M, Cagnetta A, Cirmena G, Garuti A, Rocco I, Palermo C, Pierri I, Reverberi D, Nencioni A, Ballestrero A, Gobbi M, Carella AM, Patrone F.

Leuk Lymphoma. 2013 Feb;54(2):342-52. doi: 10.3109/10428194.2012.708752. Epub 2012 Sep 5.

PMID:
22762548
9.

WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia.

Miglino M, Colombo N, Pica G, Grasso R, Clavio M, Bergamaschi M, Ballerini F, Ghiso A, Ghiggi C, Mitscheunig L, Beltrami G, Cagnetta A, Vignolo L, Lucchetti MV, Aquino S, Pierri I, Sessarego M, Carella AM, Gobbi M.

Leuk Lymphoma. 2011 Oct;52(10):1961-9. doi: 10.3109/10428194.2011.585673.

PMID:
21942328
10.

Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells.

Cea M, Soncini D, Fruscione F, Raffaghello L, Garuti A, Emionite L, Moran E, Magnone M, Zoppoli G, Reverberi D, Caffa I, Salis A, Cagnetta A, Bergamaschi M, Casciaro S, Pierri I, Damonte G, Ansaldi F, Gobbi M, Pistoia V, Ballestrero A, Patrone F, Bruzzone S, Nencioni A.

PLoS One. 2011;6(7):e22739. doi: 10.1371/journal.pone.0022739. Epub 2011 Jul 27.

11.

Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.

Balleari E, Clavio M, Arboscello E, Bellodi A, Bruzzone A, Del Corso L, Lucchetti MV, Miglino M, Passalia C, Pierri I, Ponassi I, Oneto C, Racchi O, Scudeletti M, Vignolo L, Zoppoli G, Gobbi M, Ghio R.

Leuk Res. 2011 Nov;35(11):1472-6. doi: 10.1016/j.leukres.2011.05.025. Epub 2011 Jul 26.

PMID:
21794914
12.

Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.

Gugliotta L, Tieghi A, Tortorella G, Scalzulli PR, Ciancia R, Lunghi M, Cacciola E, Cacciola R, Candoni A, Crugnola M, Codeluppi K, Usala E, Specchia G, Martinelli V, Palmieri F, Pierri I, Liberati AM, Iurlo A, Grossi A, Vannucchi AM, Vianelli N, Mazzucconi MG.

Leuk Res. 2011 Dec;35(12):1557-63. doi: 10.1016/j.leukres.2011.06.030. Epub 2011 Jul 20.

PMID:
21764130
13.

Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.

Catellani S, Pierri I, Gobbi M, Poggi A, Zocchi MR.

PLoS One. 2011 Apr 18;6(4):e18925. doi: 10.1371/journal.pone.0018925.

14.

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party.

Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M, Rosti G; Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party.

Blood. 2011 May 26;117(21):5591-9. doi: 10.1182/blood-2010-12-324228. Epub 2011 Mar 30.

PMID:
21450900
15.

Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis.

Aquino S, Clavio M, Rossi E, Vignolo L, Miglino M, Spriano M, Canepa L, Catania G, Pierri I, Bergamaschi M, Gonella R, Marani C, Racchi O, Cavaliere M, Goretti R, Carbone F, Bruzzone A, Tassara R, Carella AM, Ghio R, Gobbi M.

Oncol Lett. 2011 Mar;2(2):289-295. Epub 2011 Jan 21.

16.

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.

Palandri F, Castagnetti F, Iacobucci I, Martinelli G, Amabile M, Gugliotta G, Poerio A, Testoni N, Breccia M, Bocchia M, Crugnola M, Rege-Cambrin G, Martino B, Pierri I, Radaelli F, Specchia G, Pane F, Saglio G, Rosti G, Baccarani M.

Haematologica. 2010 Aug;95(8):1415-9. doi: 10.3324/haematol.2009.021246. Epub 2010 Mar 19.

17.

Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia.

Carella AM, Garuti A, Cirmena G, Catania G, Rocco I, Palermo C, Pica G, Pierri I, Miglino M, Ballestrero A, Gobbi M, Patrone F.

Leuk Lymphoma. 2010 Feb;51(2):275-8. doi: 10.3109/10428190903503446.

PMID:
20038234
18.

APO866 activity in hematologic malignancies: a preclinical in vitro study.

Cea M, Zoppoli G, Bruzzone S, Fruscione F, Moran E, Garuti A, Rocco I, Cirmena G, Casciaro S, Olcese F, Pierri I, Cagnetta A, Ferrando F, Ghio R, Gobbi M, Ballestrero A, Patrone F, Nencioni A.

Blood. 2009 Jun 4;113(23):6035-7; author reply 6037-8. doi: 10.1182/blood-2009-03-209213. No abstract available.

PMID:
19498032
19.

Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa.

Clavio M, Ghiso A, Ghiggi C, Spriano M, Colombo N, Grasso R, Varaldo R, Miglino M, Pierri I, Olcese F, Aquino S, Biasco S, Balleari E, Carella AM, Sessarego M, Gobbi M.

Oncol Rep. 2009 Apr;21(4):1045-52.

PMID:
19288007
20.

The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience.

Olcese F, Clavio M, Rossi E, Spriano M, Ballerini F, Canepa L, Pierri I, Aquino S, Varaldo R, Manna A, Secondo V, Racchi O, Balleari E, Orcioni GF, Carella AM, Ghio R, Gobbi M.

Ann Hematol. 2009 Sep;88(9):855-61. doi: 10.1007/s00277-009-0699-5. Epub 2009 Feb 3.

PMID:
19189105
21.

Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate.

Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR.

Leukemia. 2009 Apr;23(4):641-8. doi: 10.1038/leu.2008.354. Epub 2009 Jan 8.

PMID:
19151770
22.

Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases.

Malagola M, Peli A, Damiani D, Candoni A, Tiribelli M, Martinelli G, Piccaluga PP, Paolini S, De Rosa F, Lauria F, Bocchia M, Gobbi M, Pierri I, Zaccaria A, Zuffa E, Mazza P, Priccolo G, Gugliotta L, Bonini A, Visani G, Skert C, Bergonzi C, Roccaro AM, Filì C, Fanin R, Baccarani M, Russo D.

Eur J Haematol. 2008 Nov;81(5):354-63. doi: 10.1111/j.1600-0609.2008.01122.x. Epub 2008 Aug 19.

PMID:
18637030
23.

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A.

J Clin Oncol. 2007 Aug 20;25(24):3746-52. Epub 2007 Jul 23.

PMID:
17646666
24.

Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients.

Clavio M, Vignolo L, Albarello A, Varaldo R, Pierri I, Catania G, Balocco M, Michelis G, Miglino M, Manna A, Balleari E, Carella AM, Sessarego M, Van Lint MT, Bacigalupo A, Gobbi M.

Br J Haematol. 2007 Jul;138(2):186-95.

PMID:
17593025
25.

CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis.

Laurent S, Palmisano GL, Martelli AM, Kato T, Tazzari PL, Pierri I, Clavio M, Dozin B, Balbi G, Megna M, Morabito A, Lamparelli T, Bacigalupo A, Gobbi M, Pistillo MP.

Br J Haematol. 2007 Feb;136(4):597-608.

PMID:
17367412
26.

Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.

Malagola M, Damiani D, Martinelli G, Michelutti A, Cesana B, Vivo AD, Piccaluga PP, Ottaviani E, Candoni A, Geromin A, Tiribelli M, Fanin R, Testoni N, Lauria F, Bocchia M, Gobbi M, Pierri I, Zaccaria A, Zuffa E, Mazza P, Priccolo G, Gugliotta L, Bonini A, Visani G, Skert C, Bergonzi C, Roccaro AM, Filí C, Baccarani M, Russo D.

Br J Haematol. 2007 Jan;136(1):87-95.

PMID:
17222198
27.

In vivo apoptosis of CD8(+) lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-I and Fas ligand.

Contini P, Zocchi MR, Pierri I, Albarello A, Poggi A.

Leukemia. 2007 Feb;21(2):253-60. Epub 2006 Dec 14.

PMID:
17170722
28.

Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia.

Miglino M, Grasso R, Varaldo R, Fugazza G, Colombo N, Clavio M, Canepa L, Garuti A, Ibatici A, Pierri I, Ballerini F, Sessarego M, Gobbi M.

Leuk Lymphoma. 2006 Jul;47(7):1348-51.

PMID:
16923567
29.

Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells.

de Totero D, Meazza R, Zupo S, Cutrona G, Matis S, Colombo M, Balleari E, Pierri I, Fabbi M, Capaia M, Azzarone B, Gobbi M, Ferrarini M, Ferrini S.

Blood. 2006 May 1;107(9):3708-15. Epub 2006 Jan 3.

PMID:
16391014
30.

Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors.

Poggi A, Prevosto C, Massaro AM, Negrini S, Urbani S, Pierri I, Saccardi R, Gobbi M, Zocchi MR.

J Immunol. 2005 Nov 15;175(10):6352-60.

31.

Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.

Clavio M, Garrone A, Pierri I, Michelis GL, Balocco M, Albarello A, Varaldo R, Canepa P, Miglino M, Ballerini F, Canepa L, Gobbi M.

Oncol Rep. 2005 Oct;14(4):933-40.

PMID:
16142354
32.

Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia.

Clavio M, Pierri I, Venturino C, Garrone A, Canepa L, Miglino M, Varaldo R, Ballerini F, Michelis GL, Balocco M, Abdall N, Gatto S, Gobbi M.

Leuk Lymphoma. 2004 Dec;45(12):2527-30. No abstract available.

PMID:
15621773
33.

Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112).

Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A, Falco M, Lanino E, Pierri I, Zambello R, Bacigalupo A, Mingari MC, Moretta A, Moretta L.

Blood. 2005 Mar 1;105(5):2066-73. Epub 2004 Nov 9.

PMID:
15536144
34.

Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.

Clavio M, Venturino C, Pierri I, Garrone A, Miglino M, Canepa L, Balleari E, Balocco M, Michelis GL, Ballerini F, Gobbi M.

Ann Hematol. 2004 Nov;83(11):696-703. Epub 2004 Aug 18.

PMID:
15322763
35.

Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B.

Bassetti M, Bisio F, Di Biagio A, Pierri I, Balocco M, Soro O, Cruciani M, Bassetti D.

J Antimicrob Chemother. 2004 Aug;54(2):575-7. Epub 2004 Jul 1. No abstract available.

PMID:
15231763
36.

Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.

Clavio M, Gatto S, Beltrami G, Quintino S, Canepa L, Pierri I, Galbusera V, Carrara P, Miglino M, Varaldo R, Ballerini F, Venturino C, Cerri R, Risso M, Balleari E, Carella AM, Sessarego M, Ghio R, Bacigalupo A, Gobbi M.

J Exp Clin Cancer Res. 2002 Dec;21(4):481-7.

PMID:
12636093
37.

Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse.

Miglino M, Berisso G, Grasso R, Canepa L, Clavio M, Pierri I, Pietrasanta D, Gatto S, Varaldo R, Ballerini F, Verdiani S, Casarino L, DeStefano F, Sessarego M, Dominietto A, Raiola AM, Bregante S, di Grazia C, Gobbi M, Bacigalupo A.

Bone Marrow Transplant. 2002 Nov;30(9):579-85.

38.

CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells.

Pistillo MP, Tazzari PL, Palmisano GL, Pierri I, Bolognesi A, Ferlito F, Capanni P, Polito L, Ratta M, Pileri S, Piccioli M, Basso G, Rissotto L, Conte R, Gobbi M, Stirpe F, Ferrara GB.

Blood. 2003 Jan 1;101(1):202-9. Epub 2002 Aug 15.

PMID:
12393538
39.

Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia.

Russo D, Piccaluga PP, Michieli M, Michelutti T, Visani G, Gugliotta L, Bonini A, Pierri I, Gobbi M, Tiribelli M, Fanin R, Piccolrovazzi S, Baccarani M.

Ann Hematol. 2002 Aug;81(8):462-6. Epub 2002 Aug 27.

PMID:
12224004
41.

Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?

Clavio M, Quintino S, Venturino C, Ballerini F, Varaldo R, Gatto S, Galbusera V, Garrone A, Grasso R, Canepa L, Miglino M, Pierri I, Gobbi M.

J Exp Clin Cancer Res. 2001 Sep;20(3):351-8. Review.

PMID:
11718214
42.

Thalidomide in agnogenic and secondary myelofibrosis.

Canepa L, Ballerini F, Varaldo R, Quintino S, Reni L, Clavio M, Miglino M, Pierri I, Gobbi M.

Br J Haematol. 2001 Nov;115(2):313-5.

PMID:
11703326
43.

Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens.

Clavio M, Quintino S, Masoudi B, Carrara S, Cerri R, Pierri I, Canepa L, Miglino M, Muner P, Damasio E, Gobbi M.

J Exp Clin Cancer Res. 2001 Jun;20(2):165-73.

PMID:
11484970
44.

Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin's lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation.

Miglino M, Santini G, Grasso R, Pietrasanta D, Clavio M, Pierri I, Canepa L, Nati S, Ballerini F, Varaldo R, Palmisano G, Gobbi M.

Haematologica. 2001 Jul;86(7):706-14.

45.

Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia.

Russo D, Pricolo G, Michieli M, Michelutti A, Raspadori D, Bertone A, Marin L, Pierri I, Bucalossi A, Zuffa E, De Vivo A, Mazza P, Gobbi M, Lauria F, Zaccaria A, Baccarani M.

Leuk Lymphoma. 2001 Jan;40(3-4):335-43.

PMID:
11426555
46.

First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia.

Clavio M, Gatto S, Beltrami G, Cerri R, Carrara P, Pierri I, Canepa L, Miglino M, Balleari E, Masoudi B, Damasio E, Ghio R, Sessarego M, Gobbi M.

Leuk Lymphoma. 2001 Jan;40(3-4):305-13.

PMID:
11426552
47.

Detection of minimal residual disease in B-lymphoproliferative disorders: a three step SSCP-PCR method.

Miglino M, Grasso R, Pietrasanta D, Palmisano GL, Berisso G, Clavio M, Pierri I, Santini G, Canepa L, Gobbi M.

J Exp Clin Cancer Res. 2001 Mar;20(1):95-101.

PMID:
11370837
48.

GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly.

Pierri I, Clavio M, Beltrami G, Cavaliere M, Lanza L, Miglino M, Canepa L, Pietrasanta D, Ballerini F, Quintino S, Gatto S, Celesti L, Carrara P, Varese P, Gobbi M.

J Exp Clin Cancer Res. 1999 Mar;18(1):55-60.

PMID:
10374678
49.

GM-IVA, a short induction course for de novo acute myeloid leukemia, suitable for the elderly.

Pierri I, Clavio M, Miglino M, Cavaliere M, Pietrasanta D, Gobbi M.

Haematologica. 1999 Jun;84(6):562-3. No abstract available.

50.

First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease.

Clavio M, Miglino M, Spriano M, Pietrasanta D, Vallebella E, Celesti L, Canepa L, Pierri I, Cavaliere M, Ballerini F, Beltrami G, Rossi E, Vimercati R, Bruni R, Congiu M, Nati S, Damasio E, Santini G, Gobbi M.

Eur J Haematol. 1998 Sep;61(3):197-203.

PMID:
9753416

Supplemental Content

Loading ...
Support Center